Edgewise Therapeutics Increases R&D Spending, Eyes Drug Milestones

Edgewise Therapeutics Inc. has significantly increased its investment in research and development during the fourth quarter of the 2025 fiscal year, aiming to advance its drug candidates targeting muscle diseases. The Boulder-based biopharmaceutical company reported R&D expenses of $43.6 million, up from $37.5 million in the previous quarter. Additionally, general and administrative costs rose from $9.4 million to $12.4 million in the same period.

The company’s net loss for Q4 2025 stood at $50.2 million, compared to a loss of $40.7 million in the third quarter. This increase in spending reflects a strategic push as Edgewise accelerates clinical development for its promising therapeutic candidates.

Strategic Focus on Drug Development

In a prepared statement, Edgewise CEO Kevin Koch emphasized the company’s commitment to delivering innovative treatments. He noted, “Following strong execution in 2025, we have entered a transformative year, with development milestones and trial results expected for several of Edgewise’s drug candidates.”

Koch highlighted that the company is approaching several near-term catalysts, which he believes will bring them closer to providing effective solutions for patients suffering from serious conditions that currently lack adequate treatment options.

Edgewise’s pipeline includes sevasemten, a fast-skeletal myosin inhibitor designed to mitigate muscle damage caused by contractions in patients with muscular dystrophies. Another candidate, EDG-15400, is focused on addressing heart failure. These projects represent significant advancements in therapeutic options for conditions with substantial unmet medical needs.

As Edgewise navigates through this critical phase, the biopharmaceutical landscape continues to evolve, and the company’s heightened investment in R&D positions it as a key player in the fight against debilitating muscle diseases. The upcoming milestones are anticipated to further define the company’s trajectory and impact within the healthcare sector.

This article was initially published by BizWest, an independent news organization, and is distributed under a license agreement. © 2026 BizWest Media LLC.